Monday, April 13, 2015

Alfacalcidol IV vs PO

  • There is no good evidence to support that IV is superior over PO in terms of therapeutic superiority and improvements in clinical outcomes
  • IV is more costly than PO form (about 6-8 times more)
  • In one study, it supports the use of PO alfalcidol over IV in chronic haemodialysis patients as PO administration gives similar control of SHPT with lower doses, and is more cost-effective.
References:
1. Alfacalcidol intravenous injection. http://www.health.gov.on.ca/en/pro/programs/drugs/ced/pdf/one_alpha.pdf
2. Comparison of oral and intravenous Alfacalcidol in chronic haemodialysis patients. http://www.biomedcentral.com/1471-2369/15/27

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.